A simple test to identify diseases from dying cells could save lives
Prof. Yuval Dor and Dr. Ruth Shemer receive Kaye Innovation Award for developing a way to detect specific tissue damage from a blood sample
One of the holy grails of medical research is the development of a simple non-invasive test that can detect a variety of diseases with high accuracy. However to date there is no single diagnostic test that fulfills this function.
To solve this problem, Prof. Yuval Dor and Dr. Ruth Shemer at the Hebrew University of Jerusalem (together with Prof. Ben Glaser, Head of the Endocrinology Department at the Hadassah Medical Center) developed a new blood test that looks for the remnants of dying cells cast off by specific tissue types throughout the body.
When cells die, they release DNA fragments into the circulatory system. The DNA of each type of dying cell carries a unique chemical modification called methylation. By detecting the unique methylation signatures of DNA from the fragments of dying cells, Prof. Dor and Dr. Shemer have established a way to detect multiple disease processes —including diabetes, cancer, traumatic injury and neurodegeneration — in a highly sensitive and specific manner.
Prof. Dor and Dr. Shemer are researchers at the Institute for Medical Research-Israel Canada (IMRIC) in the Hebrew University’s Faculty of Medicine. Both earned their PhDs at the Hebrew University.
Goal: a rapid blood test to assess multiple diseases simultaneously
A test that accurately pinpoints tissue damage from dying cells’ DNA fragments could hold the key to a variety of medical advances — from a deeper understanding of human tissue dynamics, to earlier detection of life-threatening illnesses, to more efficient monitoring of responses to medical therapies.
Prof. Dor and Dr. Shemer envision a future where the continued research and refinement of their new technology will lead to a universal, rapid, sensitive and quantitative blood test for tissue-specific cell death. This blood test could be used to assess multiple pathologic conditions simultaneously, equivalent to standard blood chemistry panels in use today.
Their paper describing the method and its applications was published the Proceedings of the National Academy of Sciences, in 2016, drawing considerable interest from the scientific and popular media.
Aurum Ventures MKI Ltd., the technology investment arm of Morris Kahn, provided Yissum, the Technology Transfer arm of the Hebrew University, with $1.2 million of funding for research and